An open-label study to evaluate the safety of weekly intravenous infusions of alpha1-proteinase inhibitor (human) with alpha1 antitrypsin deficiency (AATD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225207

Enrollment

Registered

2020-05-26

Start date

2020-06-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alpha1 antitrypsin deficiency

Interventions

investigational material(s) Generic name etc : Alpha-1 MP INN of investigational material : - Therapeutic category code : 229 Other agents affecting respiratory organs Dosage and Administration for In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who didn't participate JapicCTI-163160 and whose serum alpha1 PI concentration is <50mg/dL

Exclusion criteria

Exclusion criteria: Subjects who participated JapicCTI-163160

Design outcomes

Primary

Measure	Time frame
safety Safety evaluation	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026